Welcome to our dedicated news page for LifeMD (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on LifeMD .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LifeMD 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LifeMD 's position in the market.
Rhea-AI Summary
LifeMD, Inc. (LFMD) will participate in the Maxim Group 2024 Healthcare IT Virtual Conference on January 24-25, 2024. The company's management will engage in a virtual fireside chat and one-on-one meetings, offering investors an opportunity to engage with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) expects revenue between $195 and $205 million, a 31% to 38% increase over 2023 guidance. Adjusted EBITDA is expected to be between $18 and $22 million, a 71% to 110% increase over the midpoint of 2023 guidance. The company also anticipates positive full-year free cash flow with estimated year-end 2023 cash exceeding $30 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (Nasdaq: LFMD) authorizes a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP), payable on January 15, 2024, to holders of record on January 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
Rhea-AI Summary
LifeMD, Inc.TM (Nasdaq: LFMD) announced a strategic alliance with Medifast (NYSE: MED) to integrate LifeMD’s telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided, healthy lifestyle solution. Medifast has invested $20 million, including a $10 million payment in support of the collaboration and a $10 million purchase of LifeMD common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
-
Rhea-AI Summary
Medifast (MED) expands into the medically supported weight loss market through a collaboration with LifeMD (LFMD), making a $20 million capital commitment to drive growth. The company will discontinue its quarterly cash dividend to invest in customer acquisition and experience, aiming to reignite growth in the health and wellness landscape. The collaboration is expected to address the escalating obesity crisis and tap into the $100 billion weight loss market by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) to Participate in RWJBarnabas Health Telehealth Symposium, Showcasing the Role of Telehealth in Quality Patient Care
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags
Rhea-AI Summary
LifeMD, Inc. (LFMD) to participate in upcoming investor conferences and panel discussions. CEO Justin Schreiber to discuss GLP-1s at Cantor Fitzgerald panel and digital health at BTIG forum. Sidoti's Small-Cap Virtual Conference to feature corporate overview and one-on-one investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (Nasdaq: LFMD) reported a 23% year-over-year revenue increase to $38.6 million, with record revenues for telehealth and WorkSimpli. Adjusted EPS was $0.08 per share, compared to a loss of $0.03 in the previous year. Weight Management revenue more than quadrupled, and telehealth subscribers grew 22% to a record 207,000 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
-
Rhea-AI Summary
LifeMD (NASDAQ: LFMD) achieved 855% revenue growth, ranking 166 on the Deloitte Technology Fast 500™. The growth is attributed to the differentiated, end-to-end care platform and affiliated medical group, supporting offerings like the LifeMD Weight Management Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
Rhea-AI Summary
LifeMD, Inc. will report financial results for Q3 2023 on November 8th and host a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
LifeMD, Inc.
Nasdaq:LFMD
LFMD Rankings
LFMD Stock Data
454.99M
30.96M
19.81%
30.8%
6.78%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
NEW YORK
About LFMD
lifemd is a comprehensive one-stop telemedicine/telehealth solution with a platform that provides a fully integrated telehealth solution to connect physicians, medical providers, pharmacists, and patients worldwide. the platform is hipaa-compliant and all interactions and communication between physicians, healthcare providers and patients are aes-encrypted. the platform allows physicians, healthcare providers and patients to securely connect and manage common medical conditions. lifemd also custom fabricates mobile diagnostic telehealth equipment such as cases, carts and kiosks. the service is available 24/7/365.